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ORIGINAL ARTICLE
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with chronic hepatitis C genotype 4 in the era of DAAs
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aEndocrinology Unit, Department of Internal Medicine, Minia School of Medicine, Minia University, Minia, Egypt; bHepatology Unit,
Department of Internal Medicine, Minia School of Medicine, Minia University, Minia, Egypt; cDepartment of Clinical Pathology, Minia
School of Medicine, Minia University, Minia, Egypt
ABSTRACT
Chronic hepatitis C virus (HCV) infection is associated with altered metabolism, including
dyslipidemia and insulin resistance. These contribute to disease progression and influ-
ences the response to therapy. To investigate the relationships of new direct-acting
antiviral drugs, simeprevir/sofosbuvir, with lipid profile and insulin resistance (IR). Eighty
chronic hepatitis C genotype 4 patients were included; they were divided into four
groups according to the severity of fibrosis as detected by fibroscan. Forty healthy
persons volunteered as a control group. Lipid profile changes and IR were analyzed at
baseline and after the end of treatment, and any effect of these changes on the
response to treatment was studied. Before treatment, the levels of serum triglycerides
were significantly higher in patients than in the control, and the levels of fasting insulin
showed a progressive increase with advancing stage of fibrosis. At the end of treatment,
there were a significant reduction in serum triglycerides, FBS, fasting insulin, and home-
ostasis model for the assessment of IR (P < 0.001), and a significant elevation of serum
cholesterol and low-density lipoprotein (LDL)-c, high-density lipoprotein (HDL)-c, and
LDL/HDL ratio (P = 0.001). An end-of-treatment response (week 12) was achieved in
(99%) of the treated cases with 99% sustained viral response for 12 weeks post-treat-
ment (week 24). Significant lipid profile changes were detected at the end of treatment.
Serum lipid levels and IR are no longer predictors of response to DAAs. Follow-up of the
lipid profile is warranted to avoid any possible remote effect of atherosclerotic heart
disease.
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1. Introduction
Hepatitis C virus (HCV) represents the major causative
agent of chronic liver disease affecting more than 170
million patients worldwide [1]. Chronic hepatitis C
(CHC) could be considered a special type of metabolic
disease involving insulin resistance (IR), hepatic stea-
tosis, and modulation of lipid-cholesterol biosynthesis
that may lead to fatty liver, hypo-betalipoproteinemia,
hypercholesterolemia, and increased risk for ischemic
heart diseases (IHD) [2,3]. The association between
chronic HCV infection and increased prevalence of IR
and type 2 diabetes mellitus (DM) was extensively
reported [4]. IR was reported to accelerate fibrosis in
chronic HCV-infected patients [5,6], which may lead to
increased risk of cirrhosis and hepatocellular carci-
noma [7] and has been associated with reduced rate
of sustained virological response (SVR) in response to
pegylated interferon (IFN)-α and ribavirin therapy [8].
In most countries, treatment of chronic HCV infec-
tion was shifted from IFN-based to IFN-free regimens
using direct-acting antiviral drugs (DAAs). Although
the association of baseline metabolic characteristics
with treatment outcome has not been fully assessed
for DAAs, this group was reported to result in
improved rates of SVR and to reduce the predictive
ability of these factors except for the baseline low-
density lipoprotein (LDL) [9]. The highest prevalence
of HCV was reported in Egypt, where genotype 4 is
responsible for 91% of infections [10] and DAAs repre-
sented the main line of treatment in most centers
[11]. Although the changes in lipid metabolism after
treatment with DAAs were reported for other geno-
types [12–14], it was not studied in genotype 4
infected patients. The aim of this study was to evalu-
ate the outcome of using SIM/SOF in treating geno-
type 4 infected patients and to study the relationship
of these agents with lipid profile and IR.
2. Patients and methods
Of 600 CHC patients who attended the liver unit at our
hospital in the period between February 2015 and
January 2016, 80 patients met the inclusion criteria for
this case-control study. The inclusion criteria were age
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≥18 years, nondiabetic naïve patients with compensated
CHC after HCV-4 infection, based on the presence of anti-
HCV and detectable serum HCV-RNA for 6 months or
more,whohaddifferent grades of fibrosis (F) as estimated
by fibroscan, and will be treated with (SIM/SOF). The
exclusion criteria were DM, patients who used lipid-low-
ering agents, as it could affect lipid metabolism or IR, and
patients suffering coexisting liver disease as hepatitis B
virus, human immunodeficiency virus, schistsoma infec-
tion, autoimmune hepatitis, etc. DM was defined with a
fasting glucose of≥126mg/dL according to the American
Diabetes Association criterion. Forty healthy volunteers,
20 males, and 20 females were randomly selected from
the medical and paramedical staff working in the same
hospital after their agreement to participate in the study
as control subjects. Their age ranged from 20 to 60 years.
3. Treatment protocol
Each patient consumed one SIM 150 mg capsule
and one SOF 400 mg tablet once a day (Od) for
12 weeks. The dose of SOF was reduced to a
200 mg tablet Od, if the glomerular filtration rate
dropped below 30 mL/min,
4. Ethics and informed consent
After approval by the local institutional ethics committee,
and an individual agreement of each participant in the
study, informed consent was obtained from each partici-
pant. The study was conducted in accordance with the
ethical guidelines of the Declaration of Helsinki and
International Conference on Harmonization Guidelines
for Good Clinical Practice.
5. Clinical and laboratory assessment
All participants underwent full history taking and thor-
ough clinical examination with special stress on age,
gender, daily alcohol intake (g/day) in the past
6 months, route of HCV transmission, body mass
index (BMI), and waist circumference. BMI was calcu-
lated as weight divided by the square of the height
(kg/m2). The waist circumference was measured 1 inch
above the navel or midpoint between the lower mar-
gin of the least palpable rib and the top of the iliac
crest parallel to the floor. Venous blood was drawn
after 8 hours of overnight fasting to determine the
serum levels of alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), albumin, bilirubin, platelet
count, international normalized ratio (INR), serum glu-
cose, and insulin. Then, the patients continued fasting
to complete 12 hours for assessment of total choles-
terol (TC), high-density lipoprotein (HDL) cholesterol
(HDLc), LDL cholesterol (LDLc), and triglycerides by
automated procedures. Serum insulin was determined
by electro-chemiluminescence immunoassay (Elecsys
2010; Roche Diagnostics, Indianapolis, IN). Insulin resis-
tance was investigated by the homeostasis model for
the assessment of IR (HOMA-IR) using the standard
formula: HOMA-IR = fasting insulin (uU/mL) × fasting
glucose (mmol/L)/22.5. HCV genotype was detected
using a line probe assay or reverse hybridization
(InnoLipa; Innogenetics, Genetics, Gent, Belgium).
6. Assessment of HCV-RNA load and viral
kinetics
HCV-RNA levels were assessed at baseline, at end of
treatment (week 12), and at 12 weeks after completion
of treatment (week 24). Assessment was done using
the Roche COBAS TaqMan HCV assay V.2.0 (lower limit
of detection 15 IU/m). Undetectable HCV-RNA at end-
of-treatment response (EOTR) was defined as an unde-
tectable HCV-RNA at the completion of HCV therapy.
Undetectable HCV-RNA 12 weeks after completion of
HCV therapy (week 24) was defined as SVR 12.
7. Statistical analyses
Symmetrically distributed continuous variables were
summarized as a mean ± standard deviation (SD). The
median and interquartile ranges were used for skewed
continuous variables. The variables were compared
between the groups by the Mann–Whitney U test and
the Student t-test for continuous variables, and the χ2 or
Fisher exact probability test was used for categorical data.
The two-tailed paired Student t-test was used to test the
significance of differences between baseline and post-
treatment lipid profile, metabolic factors, and HOMA-IR.
The Pearson correlation coefficients were used for the
correlation between different parametric variables.
Spearman rank correlation was used to quantify the
association between continuous or ordered categorical
variables. Logistic regression analysis was used to model
the association between baseline lipid profile, HOMA-IR,
and other covariates to determine the factors associated
with hepatic fibrosis and changes in LDL-c. P ≤ 0.05 was
considered statistically significant. SPSS software for
Windows version 20 (SPSS Inc., Chicago, IL) was used to
perform all analyses.
8. Results
8.1. Demographic and baseline characteristics
We studied 80 patients with CHC (genotype 4), trea-
ted with SIM+SOF. Their demographic, biochemical,
metabolic, and fibroscan data are detailed in Table 1.
Their mean age was 47.5 ± 12.3 years (range
20–67 years). Forty-eight patients were males, and
32 were females. The mean BMI was 22.2 ± 1.8 kg/m2
(range 16–26 kg/m2), and the mean waist/hip ratio
was 0.93 ± 0.019 (range 0.9–0.97). In 45% of patients,
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HOMA-IR was >3. Fibroscan examination revealed 36
patients with mild fibrosis (15 cases were F1, and 21
cases were F2), while 44 patients had moderate to
severe fibrosis (16 cases were F3, and 28 cases
were F4).
9. Lipid and metabolic factors
The levels of serum triglycerides, fasting blood glu-
cose (FBS), fasting insulin, and HOMA-IR were signifi-
cantly higher in patients compared with the control
(P = 0.006, 0.01, 0.001, and 0.001 respectively),
Table 2. With increasing hepatic fibrosis, a significant
increase was detected in fasting insulin level
(19.2 ± 5.4 in F0–F2, 21.7 ± 4 in F3–F4, P = 0.01), but
nonsignificant differences were detected in the lipid
profile, fasting glucose, and HOMA-IR, Table 3.
10. Changes in laboratory data, imaging,
metabolic, and lipid markers
Patients who achieved EOTR showed significant
reduction in hemoglobin, serum AST and ALT levels
(P = 0.001), fibrosis stages, which were clearly shown
in FEB4 (P = 0.03) and fibroscan (P = 0.001; Table 4).
Also, a significant reduction in serum triglycerides,
FBS, fasting insulin and HOMA-IR (P < 0.001), and a
significant elevation of serum cholesterol, LDLc and
HDLc (P = 0.001), and LDL/HDL ratio (P = 0.04) were
detected, Table 5, Figure 1.
11. Virological outcomes
Measurements of HCV-RNA at completion of therapy
(12 weeks) were undetectable (EOTR) in 79 cases
(99%). The only one nonresponding case was a 66-
year-old man with a high viral load (6.9), cirrhotic liver
and splenomegaly, and his fibroscan score was 22–24.
Measurements of HCV-RNA 12 weeks after completion
of therapy (24 weeks) were undetectable (SVR 12) in
99% of the followed cases.
Table 1. Demographic and baseline characteristics of chronic
hepatitis C patients.
Variable
Patients (n = 80)
Mean ± SD
Age (years) 47 ± 12 (20–67)
Gender (male/female) 47/33
BMI (kg/m2) 22.28 ± 1.9 (16–25)
Hypertension (yes/no) 6/59 (9.2%/90.8%)
Smoking (yes/no) 8/72 (10%/90%)
Waist/hip ratio 0.93 ± 0.019 (0.9–0.97)
Hemoglobin (g/dL) 10–17 (13.6 ± 1.3)
Platelets (×109) 194.4 ± 58 (81–430)
Albumin (gm/L) 4.15 ± 0.6 (2.1–5.4)
INR 1.1 ± 0.1 (0.9–1.4)
Creatinine (mg/L) 0.94 ± 0.18 (0.64–1.6)
Total bilirubin (mg/L) 0.46 ± 0.2 (0.1–1.2)
ALT (IU/L) 50.1 ± 20.0 (21–103)
AST (IU/L) 50.8 ± 25.8 (17–163)
AFP 3.6 ± 3.8 (0.7–32.8)
Fasting glucose (mmol/dL) 5.04 ± 0.75 (3.33–6.67)
Insulin level (uU/L)/ml) 20.15 ± 5.13 (5–29)
HOMA-IR 4.49 ± 1.28 (1.25–7.25)
HOMA-IR (<3 and ≥3) (33 and 47) (58.8% and 41.3%)
Triglycerides (mg/dL) 98 ± 40.8 (35–225)
HDLC (mg/dL) 42.1 ± 5.8 (31–58)
LDL-C (mg/dL) 63 ± 29 (11–131)
LDL/HDL 1.7 ± 0.8
Cholesterol (mg/dL) 126 ± 28 (70–195)
Viral load (log10) 5.2 + 1.3 (2.04–7.9)





(F1, F2, F3, F4) (39–41) (48.8–51.2%)
FIB-4 1.9 ± 1.1
BMI: body mass index; ALT: alanine transaminase; AST: aspartate transa-
minase; INR: International normalized ratio; HOMA-IR: homostatsis
model assessment of insulin resistance; HDLc: high-density lipoprotein
cholesterol; AFP: alpha foetoprotein; U/S: ultrasound. P values ≤0.05
are significant.
Table 2. Baseline metabolic data and lipid profile in chronic







Mean ± SD P
Cholesterol (mg/dL) 126 ± 28 137 ± 30.8 0.1
TG (mg/dL) 100.5 ± 36.1 82 ± 27 0.006
LDL-c 63.4 ± 29 79.6 ± 33.7 0.3
HDLc 39.4 ± 5.3 45.2 ± 5.23 0.776
LDL-c/LDL-c 1.72 ± 0.8 1.74 ± 0.9 0.8
Fasting glucose (mmol/dL) 5.04 ± 0.75 4.7 ± 0.52 0.01
Fasting insulin level
(uU/L)/ml)
20.15 ± 5.13 13.15 ± 4.2 0.001
HOMA-IR 4.49 ± 1.28 2.72 ± 0.87 0.001
TG: triglycerides; LDL-c: low-density lipoprotein cholesterol; HDLc: high-
density lipoprotein cholesterol; HOMA-IR: homostatsis model assess-
ment of insulin resistance. P values ≤0.05 are significant.
Table 3. Metabolic factors, lipid profile, according to fibrosis
stage in chronic hepatitis C patients.
Variable
(F0 to F2) n (36)
Mean ±SD
(F3 to F4) n (44)
Mean ±SD P
Cholesterol (mg/DL) 127 ± 28 125 ± 28 0.9
TG (mg/dL) 102.4 ± 39 99.32 ± 4 0.7
LDL-c 63.8 ± 27.5 62 ± 30 0.4
HDLc 39.3 ± 5 39.6 ± 5.4 0.5
LDL-c/LDL-c 1.7 ± 0.8 1.69 ± 0.77 0.78
Fasting glucose (mmol/dL) 5.03 ± 0.81 5.06 ± 0.7 0.895
Fasting insulin (uU/L)/ml) 19.2 ± 5.4 21.7 ± 4.4 0. 025
HOMA-IR 4.28 ± 1.3 4.7 ± 1.24 0.154
TG: triglycerides; LDL-c: low-density lipoprotein cholesterol; HDLc: high-
density lipoprotein cholesterol; HOMA-IR: homostatsis model assess-
ment of insulin resistance. P values ≤0.05 are significant.
Table 4. Changes in laboratory data and imaging before and







Hb (g/dL) 13.6 ± 1.3 12.7 ± 1.5 0.001
Platelets (×109/L) 196.09 ± 59.1 194.6 ± 37.06 0.7
ALT (U/L) 49.8 ± 21.4 41.6 ± 14.4 0.001
AST (U/L) 50.2 ± 25.2 40.2 ± 17.3 0.001
FIB-4 1.9 ± 1.08 1.7 ± 1.1 0.03
Fibroscan 13.6 ± 10.4 12.6 ± 8.8 0.001
TG: triglycerides; LDL-c: low-density lipoprotein cholesterol; HDLc: high-
density lipoprotein cholesterol; HOMA-IR: homeostasis model assess-
ment of insulin resistance. P values ≤0.05 are significant.
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12. Factors associated with ΔLDLc values at
the end of treatment (week 12)
Patients were stratified into two groups by their
ΔLDLc levels. The high-ΔLDLc group was defined as
having a median ΔLDL-c level ≥78.0 mg/dl and
included 42 patients, while the low-ΔLDL-c group
was defined as having a median ΔLDL-c level
<78.0 mg/dl and included 38 cases.
We performed a multiple step-wise logistic regres-
sion analysis to identify the factors associated with
ΔLDL-c elevation at 12 weeks from the start of ther-
apy and the relation of increased LDLc with age,
gender, BMI, AST, ALT, albumin, bilirubin, hemoglobin,
platelets, white blood cell count, log viral load, FBS,
fasting insulin, HOMA-IR, TC, triglycerides, and HDL.
TC and stage of fibrosis were closely associated with
the ΔLDLc values [OR (95% CI: 1.066 (1.031–1.102) and
1.162 (1.018–1.328) respectively] (P ≤ 0.001 and 0.026)
respectively (Table 6).
13. Discussion
The recent development of DAAs for treatment of
viral hepatitis continues to generate much interest.
This study examined the changes in lipid profile and
IR, as well as other parameters, associated with the
use of such therapy for infection with hepatitis C type
4, which is responsible for almost all cases HCV infec-
tion in Egypt, a country with the highest rate of
hepatitis. Though other similar studies exist, few or
none of them are about type 4 HCV, on which this
study sheds some light. With continuous research, the
effects and relationships of these drugs continue to
Table 5. Changes of metabolic factors, lipid profile before and







TG (mg/dl) 100.5 ± 36 81.7 ± 31.9 0.001
Cholesterol (mg/dl) 126.1 ± 28.2 143 ± 38.5 0.001
LDL (mg/dl) 63.4 ± 28.9 84.8 ± 38.1 0.001
HDL (mg/dl) 39.4 ± 5.3 (28–51) 42.9 ± 5.9 (30–58) 0.001
LDL/HDL 1.7 ± 0.8 2 ± 0.87 0.04
FBS (mmol/L) 5.04 ± 0.75 4.7 ± 0.52 0.001
Fasting insulin
(uU/L)/ml)
20.15 ± 5.13 15.7 ± 7.4 0.001
HOMA-IR 4.49 ± 1.28 3.06 ± 0.01 0.001
TG: triglycerides; LDL-c: low-density lipoprotein cholesterol; HDLc: high-
density lipoprotein cholesterol; HOMA-IR: homeostasis model assess-
ment of insulin resistance. P values ≤0.05 are significant.
Figure 1. Changes in lipid profile, FBS, fasting insulin, and HOMA-IR in 80 chronic hepatitis C patients before and at the end of
treatment with SOF/SIM. The charts show the changes in lipid profile, FBS, fasting insulin, and HOMA-IR in chronic hepatitis C
(HCV) patients before and at the end of treatment (12 weeks) with SOF/SIM. LDL-c: low-density lipoprotein cholesterol; HDL:
high-density lipoprotein cholesterol; TG: triglycerides; FBS: fasting blood sugar.
Table 6. Factors associated with ΔLDL-C value with HCV
administered SOF/SIM regimen, analyzed by multiple logis-
tic-regression analysis.
Variable Sig. OR (95% CI)
Age (years) 0.552 1.012 (0.974–1.051)
BMI (kg/m2) 0.537 0.868 (0.554–1.361)
Gender (male/female) 0.198 1.897 (0.716–5.029)
ALT (U/L) 0.322 0.974 (0.926–1.026)
AST (U/L) 0.559 0.986 (0.939–1.035
T bilirubin (mg/L) 0.300 2.972 (0.380–23.267)
Albumin (g/L) 0.647 0.734 (0.195–2.763)
Hemoglobin (gm/dL) 0.987 0.995 (0.535–1.849)
Platelets (×109/L) 0.677 0.997 (0.983–1.011)
WBCs (×103) 0.771 1.000 (1.000–1.000)
Log of viral load (log10) 0.429 1.000 (1.000–1.000)
HOMA-IR 0.179 0.601 (0.286–1.263)
Fasting insulin (uU/L)/ml) 0.395 0.859 (0.606–1.219)
Fasting sugar (mmol/dL) 0.919 1.093 (0.196–6.097)
HOMA- IR 0.305 2.948 (0.374–23.229)
Cholesterol (mg/dL) 0.001 1.066 (1.031–1.102)
TG (mg/dL) 0.342 0.989 (0.967–1.012)
HDLC (mg/dL) 0.435 0.941 (0.807–1.097)
Stage of fibrosis (F1–F4) 0.026 1.162 (1.018–1.328)
BMI: body mass index; ALT: alanine transaminase; AST: aspartate transa-
minase; HOMA-IR: homostatsis model assessment of insulin resistance;
HDLc: high-density lipoprotein cholesterol. P values ≤0.05 are
significant.
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emerge, but many of these effects did not reach the
level of the facts and are still controversial. In concor-
dance with Buti et al. [15], the present study reached
an EOTR of 99% of the treated cases and 99% SVR-12
rate. Based on these results, the role of metabolic
factors as predictors of the DAAs has decreased or
even ameliorated. Also, the changes in lipid profile
after therapy represented an interesting finding, as
recently reported with the use DAAs [12,16]. We
found a significant reduction in serum triglycerides
and a significant elevation of serum cholesterol, LDL,
HDL, and LDL/HDL ratio at 12 weeks post-treatment.
The direct link between HCV and host lipoproteins
explicates the significant interrelationship between
HCV and host lipid metabolism, as proved both in
vitro [17] and in clinical studies [12]. Meissner et al.
[12] reported a concomitant decrease in triglycerides
and VLDL particle size and a marked increase in serum
LDLc after 24 weeks of treating HCV genotype 1
infected patients with SOF/RBV, irrespective of the
treatment outcome [12]. This might explain a direct
effect of HCV clearance on lipid metabolism.
Townsend et al. [13] reported a rapid increase in
LDLc and TC values that was also sustained after
treating HIV/HCV-coinfected patients with ledipasvir
and sofosbuvir (LDV/SOF) combination therapy for
12 weeks. Thus, the increment in serum LDLc and TC
levels occurs in both HIV/HCV-coinfected and HCV
mono-infected patients. Mauss et al. [16] reported
that the use of IFN-free DAAs regimens increased TC
levels with no effect on triglycerides, while IFN-based
therapy led to a reduction in TC levels with increased
triglycerides, followed by a re-increase in TC levels
after achieving SVR. Recently, Gitto et al. [14] reported
that the treatment of CHC patients genotype 1b led
to an improvement in IR with worsening of the lipid
profile in the form of increased HDL, LDL/HDL ratio,
apolipoprotein (APO) A1, and APO B1 after 24 weeks.
These findings might explore whether the changes in
lipid profile may be genotype-specific.
The changes in the lipid profile may differ accord-
ing to the type of DAAs. Upon treating CHC genotype
1 patients, Hashimoto et al. [18] observed a rapid
increase in LDLc and TC during the first 28 days of
treatment that was stronger in patients who received
LDV/SOF than in those who received daclatasvir/suna-
previr (DCV/ASV), while Endo et al. [19] reported a
significantly greater increase in TC and LDLc in the
SOF/LDV group than in the DCV/ASV group during
treatment, but at 4 and 12 weeks after therapy, the
serum levels of TC and LDL-c were similar in both
groups.
The factors that could predict changes in LDL levels
were inferred in a logistic regression analysis. The
main independent predictors for LDL changes in our
study were advancing stage of fibrosis and lower
cholesterol levels. This was in concordance with
Khattab et al. [20] who reported lower HDLc and
cholesterol levels in CHC genotype 4 patients with
severe hepatic fibrosis than those with mild fibrosis.
Thus, increased serum cholesterol and LDL levels after
treating patients with advanced fibrosis might repre-
sent an improvement in liver pathology or inflamma-
tion. In our study, the changes in lipid profile after
DAAs were atherogenic, which might represent a pre-
dictor for cardiovascular risk. This may justify long-
term monitoring of lipid parameters.
The HCV infection showed a complex relationship
with IR. IR appears in the early stages of HCV infection
and increases the rate and the progression of hepatic
fibrosis through compensatory hyper-insulinemia,
hepatic stellate cells increment, and type 1 collagen
proliferation [21]. Hsu et al. [22] reported a correlation
between HCV-RNA levels and HOMA-IR score. Even in
nondiabetic patients, Moucari et al. [23] reported IR in
32.4% of CHC patients. Also, despite being nonobese,
nondiabetic, or prediabetic, 45% of our patients had
IR >3, and the mean fasting insulin and HOMA-IR were
significantly higher in the patients group in compar-
ison with control subjects (20.15 ± 5.13 vs 13.15 ± 4.2,
P = 0.001) and (4.49 ± 1.28 vs 2.72 ± 0.87, P = 0.001)
respectively. Moreover, the fasting insulin showed a
progressive increase, with advancing stage of hepatic
fibrosis in agreement with Petit et al. [6], who
reported that IR in nondiabetic HCV-infected patients
was related to liver fibrosis grading and may occur
early in the course of HCV infection.
Although the relationship between the use of
DAAs and IR was not extensively studied except in a
limited number of studies [14], the high rate of SVR to
SOF/SIM-based therapy in our CHC-naïve patients
may mean that IR is no longer having a predictor
role for SVR, as that was reported for the peg-inter-
feron/ribavirin regimens. This concept was also sup-
ported by other studies [9].
Serfaty et al. [24] treated CHC genotype 1 patients
with telaprevir-based regimens. Their results revealed a
minor role of metabolic factors in influencing antiviral
response. Many studies reported that HOMA-IR did not
show any relation to SVR [9,24,25]. A significant
improvement in IR was reported in patients who
achieved SVR after treatment from HCV genotype 1
infection compared with those who did not [9,25].
Others [26–29] concluded that achieving viral clearance
significantly reduces the risk for both type 2 DM and de
novo IR in nondiabetic HCV patients. Similarly, in our
study, patients who achieved SVR showed a significant
improvement in fasting insulin and HOMA-IR.
This study had many limitations that need to be
overcome in a further study, including the low num-
ber of cases, the failure to evaluate CVD predictors
and risk factors as APO A1/APO B1 ratio and lipopro-
tein (a), the lack of analysis of dynamic changes in LDL
and IR early during therapy, the failure to link the
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significant laboratory parameters to CVD risk because
of the design/nature of this study, and the short-term
follow-up that did not allow us to determine whether
the changes in LDLc levels would continue after the
completion of treatment.
14. Conclusions
The SOF/SIM-based therapy continues to show a high
degree of effectiveness in the treatment of CHC GT4.
High SVR ameliorates the predictive effect of meta-
bolic factors as IR. The lipid changes in this study were
interesting to the extent that long-term follow-up is
strongly warranted for a better clarification of the
possible role of CHC as a potential risk for CVD.
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